MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..

Zerit (stavudine)

Company: Bristol-Myers Squibb
Approval Status: Approved December 22, 1995
Treatment for: HIV infection
Areas: Immune System
Possible similar drugs: Zerit

| General Information | Clinical Results | Side Effects | Mechanism of Action | Literature References |

General Information

Zerit is indicated for the treatment of adults with advanced HIV infection who are intolerant of approved therapies with proven clinical benefit or who have experienced significant clinical or immunologic deterioration while receiving these therapies or for whom such therapies are contraindicated.

Clinical Results

10,438 subjects participated in a randomized, double-blind, 12-week clinical trial comparing Zerit to zidovudine, another treatment for HIV infection. Subjects receiving Zerit had a mean increase in CD4+ cell count from baseline to week 12, while subjects continuing on zidovudine had a mean decrease of CD4+ cell count.

Side Effects

The major clinical toxicity of Zerit is peripheral neuropathy. This adverse event occurred in 15% to 21% of subjects in the controlled trials. Neuropathy is characterized by numbness, tingling, or pain in the feet and hands.

Mechanism of Action

Zerit inhibits the replication of HIV in human cells in vitro by two known mechanisms. First, it inhibits HIV reverse transcriptase, the process by which HIV-infected DNA is created from RNA. Second, it inhibits viral DNA synthesis by causing DNA chain termination; natural elongation of DNA chains is unable to occur.

Literature References

Sommadossi J-P, Zhu Z, Carlisle R, et al. Pharmacologic studies of nucleosides active against the human immunodeficiency virus. Annals of the NY Academy of Science 1990; 616: 356-366.

< back to top

Zerit Drug Information

The Zerit drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2016 All rights reserved.